Werewolf Therapeutics (HOWL) Liabilities and Shareholders Equity (2020 - 2026)

Werewolf Therapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $24.2 million in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $24.2 million, down 73.91% year-over-year; the trailing twelve-month figure through Jun 2026 was $231.2 million (down 50.47% YoY), and the FY2025 annual result was $69.4 million, down 45.33% from the prior year.
• Liabilities and Shareholders Equity declined to $24.2 million in Q2 2026, from $58.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $195.1 million in Q1 2023 and troughed at $24.2 million in Q2 2026.
• A 5-year average of $135.2 million and a median of $157.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity soared 84.08%; it then sank 73.91% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $160.2 million in 2022, then increased by 9.1% to $174.8 million in 2023, then declined by 27.4% to $126.9 million in 2024, then plunged by 45.33% to $69.4 million in 2025, then sank by 65.19% to $24.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $24.2 million in Q2 2026, $58.0 million in Q1 2026, and $69.4 million in Q4 2025.